ENLIVEX THERAPEUTICS LTD. Enlivex Therapeutics Ltd. Share Price Deutsche Boerse AG
Equities
1BT
IL0011319527
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 EUR | +4.27% |
|
-2.40% | -46.96% |
| 28/05 | Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall | MT |
| 22/04 | Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 27.79M 25.62M 2.32B |
|---|---|---|---|---|---|
| Net income 2024 * | -16M -14.75M -1.33B | Net income 2025 * | -12M -11.07M -1B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-2.47
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.23% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.27% | ||
| 1 week | -2.40% | ||
| 1 month | -19.74% | ||
| 3 months | -56.74% | ||
| 6 months | -26.51% | ||
| Current year | -46.96% |
1 week
1.17
1.27
1 month
1.171.49
Current year
1.173.92
1 year
1.173.92
3 years
1.1711.70
5 years
1.1736.47
10 years
1.1736.47
| Managers | Title | Age | Since |
|---|---|---|---|
Oren Hershkovitz
CEO | Chief Executive Officer | 47 | 16/19/16 |
Dror Mevorach
FOU | Founder | 68 | 01/09/01 |
| Director of Finance/CFO | 47 | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shai Novik
CHM | Chairman | 58 | 01/14/01 |
Avri Havron
BRD | Director/Board Member | 76 | 01/14/01 |
Brian Schwartz
BRD | Director/Board Member | 52 | 01/20/01 |
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 1.22 | +4.27% |
| 30/24/30 | 1.17 | -5.65% |
| 29/24/29 | 1.24 | -1.59% |
| 28/24/28 | 1.26 | -0.79% |
| 27/24/27 | 1.27 | +1.60% |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 11:35 am IST
More quotes
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Calendar
23/05/2025
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.36
USD
Average target price
7
USD
Spread / Average Target
+414.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ENLV Stock
- 1BT Stock
